Slide 1: The ADG20 human monoclonal antibody binds with high affinity and neutralises a wide range of SARS-CoV-2 variants
The ADG20 human monoclonal antibody binds with high affinity and neutralises a wide range of SARS-CoV-2 variants and zoonotic sarbecoviruses Chengzi I. Kaku,1,2 Zoltán Magyarics,1 Laura M. Walker1,2 1Adagio Therapeutics, Inc., Waltham, MA, USA; 2Adimab LLC, Lebanon, NH, USA Abstract #647 presented a
Slide 2: Disclosures
Disclosures • LMW is an inventor on a patent application submitted by Adagio Therapeutics, Inc., describing the engineered SARS-CoV-2 antibodies • CIK is an employee of Adagio Therapeutics, Inc. • ZM has received consulting fees from Adagio Therapeutics, Inc. • Editorial assistance was provided by G
Slide 3: ADG20 is a fully human IgG1 monoclonal antibody isolated from a survivor of the 2003 SARS epidemic
ADG20 is a fully human IgG1 monoclonal antibody isolated from a survivor of the 2003 SARS epidemic Yeast surface-display technology 3 leads optimisation Adagio 2 (ADG2) + Single B-cell sort Cross-neutralisers Blood sample Convalescent against SARS-CoV-2 Fc modification to ~500-fold increase in bindi
Slide 4: In vitro ADG2 shows broad and potent neutralising activity across diverse SARS-related coronaviruses
In vitro ADG2 shows broad and potent neutralising activity across diverse SARS-related coronaviruses ACE2, angiotensin-converting enzyme 2. Letko M, et al. Nat Microbiol. 2020;5:562–569 . 4
Slide 5: In vitro ADG2 shows broad and potent neutralising activity across diverse SARS-related coronaviruses
In vitro ADG2 shows broad and potent neutralising activity across diverse SARS-related coronaviruses Letko M, et al. Nat Microbiol. 2020;5:562–569. 5
Slide 6: In vitro ADG2 shows broad and potent neutralising activity across diverse SARS-related coronaviruses
In vitro ADG2 shows broad and potent neutralising activity across diverse SARS-related coronaviruses VIR-7831 (sotrovimab); REGN10987 (imdevimab); REGN10933 (casirivimab); Ly-CoV16 (etesevimab); Ly-CoV555 (bamlanivimab); AZD8895 (tixagevimab). IC50, 50% maximal inhibitory concentration; N.N., non-ne
Slide 7: ADG20 binds with high affinity to clade 1, ACE2-binding sarbecovirus RBDs
ADG20 binds with high affinity to clade 1, ACE2-binding sarbecovirus RBDs S309, the parent antibody of VIR-7831 (sotrovimab); REGN10987 (imdevimab); REGN10933 (casirivimab); Ly-CoV16 (etesevimab); Ly-CoV555 (bamlanivimab). RBDs, receptor-binding domains; KDApp, apparent dissociation constant; N.B.,
Slide 8: ADG20 maintains binding activity against commonly circulating SARS-CoV-2 isolates
ADG20 maintains binding activity against commonly circulating SARS-CoV-2 isolates Commonly observed spike mutations in the RBD S309, the parent antibody of VIR-7831 (sotrovimab); REGN10987 (imdevimab); REGN10933 (casirivimab); Ly-CoV16 (etesevimab); Ly-CoV555 (bamlanivimab). GISAID, Global Initiativ
Slide 9: ADG20 maintains neutralising activity against emerging SARS-CoV-2 variants of concern
ADG20 maintains neutralising activity against emerging SARS-CoV-2 variants of concern WHO nomenclature Alpha Beta Gamma Delta Kappa ADG20 Adagio utilized the non-clinical and pre-clinical services program offered by the US National Institute of Allergy and Broad neutralisers SARS-CoV-2–only neutrali
Slide 10: Conclusions
Conclusions • In vitro, ADG20 displayed breadth of binding to RBDs of clade 1 sarbecoviruses and SARS-CoV-2 variants resistant to many other antibody therapies • ADG20 showed potent neutralising activity against emerging SARS-CoV-2 variants of concern and pre-emergent SARS-like CoVs • ADG20 demonstr
Slide 11: Acknowledgements
Acknowledgements Garrett Rappazzo Lynn Connolly Gavin Screaton Dennis Burton Chengzi Kaku Kristin Narayan Wanwisa Dejnirattisai David Nemazee Anna Wec Becky Deborah James Voss Michael Brown Ellie Hershberger Deli Huang Jon Belk Ed Campanaro Laura Deveau Halley Gilbert James Geoghegan Paul Ambrose Mr
Slide 12: QR code
QR code Scan the QR code to download an electronic version of the presentation and to access supplemental content. The QR code is intended to provide scientific information for individual reference. The file should not be altered or reproduced in any way.